Sanofi's Libtayo Succeeds In Basal Cell Carcinoma Study
Could Be First PD-1/PD-L1 Therapy For Most Common Form Of Skin Cancer
BCC is the second non-melanoma skin cancer for which Libtayo has demonstrated efficacy as the PD-1 inhibitor, which also recently impressed in a lung cancer study, is already approved for cutaneous squamous cell carcinoma.
